Salmeterol
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1994
- First approval year
- 1994
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Salmeterol
- Molecular weight
- 415.57
- Structure (SMILES)
- OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O
- budesonide salmeterol azithromycin
- gr 33343 x
- GR 33343 X
- GR-33343-X
- salmaterol
- Salmaterol
- salmeterol
- Salmeterol
- Salmeterol (as xinafoate)
- Salmeterol (DISKUS)
- SALMETEROL [HSDB]
- salmeterol [INN]
- SALMETEROL [MI]
- SALMETEROL [USAN]
- SALMETEROL [VANDF]
- Salmeterol [WHO-DD]
- Salmeterol 50 mcg BID
- Salmeterol 50 μg
- salmeterol 50mcg
- Salmeterol 50mcg
- salmeterol hsdb
- salmeterol inn
- salmeterol mi
- salmeterol usan
- salmeterol vandf
And 4 more, listed on the interactive page.
- ATC classification codes
- R03AC12
Sources for recorded values
- CAS registry numbers
- 89365-50-4
- ChEMBL ID
- CHEMBL1263
- InChIKey
- GIIZNNXWQWCKIB-UHFFFAOYSA-N
- PubChem compound IDs
- 5152
- RxNorm IDs (RxCUI)
- 36117
- FDA ingredient codes (UNII)
- 2I4BC502BT
- Applicant
- GLAXOSMITHKLINE
- Approval date
- 4 Feb 1994
- Application number
- NDA020236
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- salmeterol
- Type
- Synthetic organic
- Drug name stem
- sal-; -terol
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β2-adrenoceptor
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Affinity units
- pEC50
- Action
- Partial agonist
- Action type
- PARTIAL_AGONIST
- Target
- β2-adrenoceptor
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Affinity units
- pKi
- Primary target
- Yes
Open Targets mechanisms
- Mechanism
- Beta-2 adrenergic receptor agonist
- Action type
- Agonist
- Target
- Beta-2 adrenergic receptor
DrugCentral mechanisms
- Action type
- Agonist
- Gene symbol
- ADRB2
- Protein identifier
- P07550
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Emphysema
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000464
- Subject identifier
- D004646
- Condition
- Lung Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003818
- Subject identifier
- D008171
- Condition
- Bronchitis, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0006505
- Subject identifier
- D029481
- Condition
- Bronchiolitis Obliterans
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007183
- Subject identifier
- D001989
- Condition
- Lung Diseases, Obstructive
- Highest recorded phase
- 4
- Condition identifier
- HP:0006536
- Subject identifier
- D008173
- Condition
- Asthma
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Spinal Cord Injuries
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0043797
- Subject identifier
- D013119
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0000464
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000684
- Condition identifier
- EFO_0006505
- Highest recorded phase
- 3
- Condition identifier
- HP_0002094
- Highest recorded phase
- 1
- Condition identifier
- HP_0006536
- Condition identifier
- HP_0006536
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0001590
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0004784
- Condition identifier
- MONDO_0004849
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005249
- Condition identifier
- MONDO_0005607
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009061
- Condition identifier
- MONDO_0043797
- Highest recorded phase
- 1
Open Targets warnings
- Warning
- Black Box Warning
- Effect
- respiratory toxicity
- Country
- United States
- Event
- adrenal insufficiency
- Reports
- 129
- Reporting signal score
- 284.707
- Event
- adrenal suppression
- Reports
- 66
- Reporting signal score
- 256.1
- Event
- allergic granulomatous angiitis
- Reports
- 3
- Reporting signal score
- 11.1262
- Event
- anosmia
- Reports
- 65
- Reporting signal score
- 146.93
- Event
- asthma
- Reports
- 1,592
- Reporting signal score
- 4,950.3
- Event
- asthma-chronic obstructive pulmonary disease overlap syndrome
- Reports
- 49
- Reporting signal score
- 239.324
- Event
- asthmatic crisis
- Reports
- 48
- Reporting signal score
- 149.481
- Event
- blood cortisol decreased
- Reports
- 39
- Reporting signal score
- 136.767
- Event
- blood count abnormal
- Reports
- 277
- Reporting signal score
- 735.075
- Event
- breath sounds abnormal
- Reports
- 65
- Reporting signal score
- 168.264
- Event
- bronchial wall thickening
- Reports
- 26
- Reporting signal score
- 91.8093
- Event
- bronchiectasis
- Reports
- 125
- Reporting signal score
- 354.928
- Event
- bursitis
- Reports
- 113
- Reporting signal score
- 271.48
- Event
- candida infection
- Reports
- 59
- Reporting signal score
- 88.1872
- Event
- central obesity
- Reports
- 26
- Reporting signal score
- 86.7186
- Event
- chest discomfort
- Reports
- 274
- Reporting signal score
- 314.619
- Event
- chronic obstructive airways disease exacerbated
- Reports
- 3
- Reporting signal score
- 15.5386
- Event
- chronic obstructive pulmonary disease
- Reports
- 333
- Reporting signal score
- 707.018
- Event
- coeliac disease
- Reports
- 114
- Reporting signal score
- 333.546
- Event
- condition aggravated
- Reports
- 262
- Reporting signal score
- 84.8289
- Event
- cough
- Reports
- 671
- Reporting signal score
- 790.856
- Event
- cushing's syndrome
- Reports
- 150
- Reporting signal score
- 468.668
- Event
- cushingoid
- Reports
- 52
- Reporting signal score
- 124.531
- Event
- drug hypersensitivity
- Reports
- 375
- Reporting signal score
- 201.227
- Event
- drug interaction
- Reports
- 14
- Reporting signal score
- 12.0288
And 55 more, listed on the interactive page.
- NCT00064402
- NCT00064415
- NCT00116402
- NCT00268177
- NCT00268216
- NCT00269087
- NCT00269126
- NCT00274534
- NCT00274560
- NCT00347139
- NCT00358488
- NCT00364273
- NCT00411372
- NCT00422604
- NCT00531050
- NCT00535366
- NCT00549146
- NCT00605891
- NCT00615030
- NCT00640484
- NCT00642148
- NCT00662740
- NCT00662792
- NCT00668772
- NCT00673478
And 97 more, listed on the interactive page.
- Dose
- 1 inhalation
- Route
- Inhalation
- How often
- Twice daily
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 4
- Polar surface area
- 81.95
- Calculated partition coefficient (ALogP)
- 4.11
- Calculated partition coefficient (XLogP)
- 3.9
- Prodrug
- No
- Chirality
- Racemic
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 16
- Heavy atoms
- 30
- Molecular formula
- C25H37NO4
- Monoisotopic mass
- 415.27225866
- Natural product
- Yes
- Recorded assays
- 1,111
- Active assays
- 171
- Confirmatory
- Other
- Screening
- Adrenergic beta-2 Receptor Agonists
Compounds bind to and activate ADRENERGIC BETA-2 RECEPTORS.
- Bronchodilator Agents
Agents that cause an increase in the expansion of a bronchus or bronchial tubes.
Distribution coefficient (LogD)
- Median
- 1.9
- Mean
- 1.77333
- Minimum
- 1.06
- Maximum
- 2.5
- Unit
- unitless
- Assays
- 9
- Standard deviation
- 0.522303
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Oral bioavailability
- Median
- 10
- Mean
- 32.4
- Minimum
- 10
- Maximum
- 66
- Unit
- %
- Assays
- 5
- Standard deviation
- 30.6725
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- F
Related records
Trials (268)
- A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
- A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
- A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma
- A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma
- A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma
- A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
- A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
- A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
- A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects
- A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
- A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers
- A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. SERETIDE DISKUS® in Healthy Volunteers With Charcoal Blockade (BREATH-PK250-CC)
- A Blinded Study To Examine The Ability Of PF-610,355 To Open The Airways In Asthmatic Patients.
- A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
- A Comparative Study To Determine If Motivating Asthma Education (Compliance Enhancement) Has An Effect On Asthma Control
- A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.
- A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
- A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma
Approved for (1)
- Obstructive lung disease
In development for (7)
- Asthma Phase 3
- Bronchiolitis obliterans syndrome Phase 3
- Chronic bronchitis Phase 3
- Chronic obstructive pulmonary disease Phase 3
- Lung disorder Phase 2
- Pulmonary emphysema Phase 3
- Spinal cord injury Phase 1
Other linked conditions (2)
- Allergic asthma
- Respiratory system disorder
Targets (1)
- ADRB2 Beta-2 adrenergic receptor agonist